The stock of Transmedics Group Inc (TMDX) has gone up by 6.84% for the week, with a 23.29% rise in the past month and a -6.99% drop in the past quarter. The volatility ratio for the week is 6.82%, and the volatility levels for the past 30 days are 6.24% for TMDX. The simple moving average for the past 20 days is 8.63% for TMDX’s stock, with a -33.91% simple moving average for the past 200 days.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
Transmedics Group Inc (NASDAQ: TMDX) has a higher price-to-earnings ratio of 82.62x compared to its average ratio. TMDX has 36-month beta value of 2.13. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TMDX is 32.43M, and currently, short sellers hold a 34.32% ratio of that float. The average trading volume of TMDX on February 25, 2025 was 1.98M shares.
TMDX) stock’s latest price update
Transmedics Group Inc (NASDAQ: TMDX)’s stock price has soared by 7.19 in relation to previous closing price of 71.95. Nevertheless, the company has seen a gain of 6.84% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-24 that NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131938&wire=1 or contact Joseph E. Levi, Esq.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with JP Morgan repeating the rating for TMDX by listing it as a “Neutral.” The predicted price for TMDX in the upcoming period, according to JP Morgan is $75 based on the research report published on December 17, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to TMDX, setting the target price at $125 in the report published on October 29th of the previous year.
TMDX Trading at 15.22% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.52% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 6.82%, as shares surge +26.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.42% upper at present.
During the last 5 trading sessions, TMDX rose by +6.84%, which changed the moving average for the period of 200-days by -41.86% in comparison to the 20-day moving average, which settled at $71.00. In addition, Transmedics Group Inc saw 23.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Khayal Tamer I, who sale 1,083 shares at the price of $80.05 back on Jan 07 ’25. After this action, Khayal Tamer I now owns 20,843 shares of Transmedics Group Inc, valued at $86,694 using the latest closing price.
Khayal Tamer I, the Chief Commercial Officer of Transmedics Group Inc, sale 1,084 shares at $86.40 during a trade that took place back on Dec 02 ’24, which means that Khayal Tamer I is holding 20,843 shares at $93,658 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.59 for the gross margin
The net margin for Transmedics Group Inc stands at 0.08. The total capital return value is set at 0.04. Equity return is now at value 19.41, with 4.43 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.47. The interest coverage ratio of the stock is 2.91.
Currently, EBITDA for the company is -7.6 million with net debt to EBITDA at 3.23. When we switch over and look at the enterprise to sales, we see a ratio of 6.92. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.20.
Conclusion
To put it simply, Transmedics Group Inc (TMDX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
